Publications by authors named "Esther Koop"
Article Synopsis
- The study investigates the prognostic significance of BRCA1-related biomarkers in young, node-negative, chemotherapy-naïve triple-negative breast cancer (TNBC) patients, focusing on how these biomarkers influence overall survival outcomes.
- It included 485 Dutch women diagnosed with TNBC under age 40, assessing their BRCA1 status and tumor-infiltrating lymphocytes (sTILs) to determine outcomes over a 15-year period.
- Results showed that patients with pathogenic germline BRCA1 mutations had worse survival rates compared to those without alterations, but higher levels of sTILs significantly improved overall survival, particularly in patients with tumor BRCA1 promoter methylation.
Article Synopsis
- - This study examined the effectiveness of the PREDICT breast cancer prognostic model for young women under 40 with node-negative breast cancer who didn’t receive systemic treatment.
- - Researchers evaluated data from the Netherlands Cancer Registry and found that PREDICT significantly underestimated 10-year mortality rates and had moderate discrimination overall, especially poor for women with ER-negative tumors.
- - The findings suggest that PREDICT is not reliable for predicting outcomes in this specific group, emphasizing the need for updates to the model before it can be used routinely for young patients.
The classification of human epidermal growth factor receptor 2 (HER2) expression is optimized to detect HER2-amplified breast cancer (BC). However, novel HER2-targeting agents are also effective for BCs with low levels of HER2. This raises the question whether the current guidelines for HER2 testing are sufficiently reproducible to identify HER2-low BC.
View Article and Find Full Text PDFPurpose: Triple-negative breast cancer (TNBC) is considered aggressive, and therefore, virtually all young patients with TNBC receive (neo)adjuvant chemotherapy. Increased stromal tumor-infiltrating lymphocytes (sTILs) have been associated with a favorable prognosis in TNBC. However, whether this association holds for patients who are node-negative (N0), young (< 40 years), and chemotherapy-naïve, and thus can be used for chemotherapy de-escalation strategies, is unknown.
View Article and Find Full Text PDFIntroduction: Currently used tools for breast cancer prognostication and prediction may not adequately reflect a young patient's prognosis or likely treatment benefit because they were not adequately validated in young patients. Since breast cancers diagnosed at a young age are considered prognostically unfavourable, many treatment guidelines recommend adjuvant systemic treatment for all young patients. Patients cured by locoregional treatment alone are, therefore, overtreated.
View Article and Find Full Text PDFBackground: Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) is a pro-apoptotic member of the Bcl-2 family induced under hypoxia. Low or absent expression has recently been described in human tumors, including gastrointestinal tumors, resulting in poor prognosis. Little is known about BNIP3 expression in invasive breast cancer.
View Article and Find Full Text PDFCertain nuclear morphometric features measured in breast tumor tissue have been shown to predict the prognosis of breast cancer patients. However, the application of these features to predicting risk of breast cancer development has received little attention. We conducted a case-control study to evaluate nuclear morphometric features in benign breast tissue in association with subsequent breast cancer risk.
View Article and Find Full Text PDF